SCHEMBL24077199

SCHEMBL24077199

O=c1[nH]nc(Br)c2cc(OC(F)(F)F)ccc12

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ PRMT5 O14744 2/20 0.46
▸ WDR77 Q9BQA1 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.43
▸ CRHBP P24387 1/20 0.43
▸ CRHR2 Q13324 1/20 0.43
▸ CES1 P23141 1/20 0.42
▸ TRPA1 O75762 5/20 0.40
▸ SCN5A Q14524 2/20 0.40
▸ NOTUM Q6P988 1/20 0.40
▸ SCN9A Q15858 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ KIF11 P52732 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ ROCK2 O75116 3/20 0.39
▸ ROCK1 Q13464 3/20 0.39
▸ GSK3B P49841 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24076283 0.79 HTT (0.44) HTTSMN1; SMN2PRMT5WDR77KDM4E
SCHEMBL24076862 0.77 MAPT (0.47) SMN1; SMN2PRMT5WDR77KDM4ETRPA1
SCHEMBL24076274 0.77 HTT (0.43) HTTSMN1; SMN2PRMT5WDR77KDM4E
SCHEMBL29655243 0.76 PARP1 (0.56) HTTSMN1; SMN2PRMT5WDR77
SCHEMBL19748759 0.76 PARP1 (0.56) HTTSMN1; SMN2PRMT5WDR77
SCHEMBL24076877 0.75 MAPT (0.39) HTTSMN1; SMN2PRMT5WDR77
SCHEMBL24076903 0.74 PRMT5 (0.48) PRMT5WDR77L3MBTL1ALDH1A1ROCK1
SCHEMBL26732890 0.73 PRMT5 (0.43) HTTSMN1; SMN2PRMT5WDR77L3MBTL1
SCHEMBL13717313 0.72 PRMT5 (0.53) HTTSMN1; SMN2PRMT5WDR77TRPA1
SCHEMBL24076270 0.72 ALDH1A1 (0.47) HTTSMN1; SMN2PRMT5WDR77KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
WO-2021239885-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202989-A1 COMPOUNDS NLRP3, NLRP1, IL1B HTT 3267/4885SMN1; SMN2 4739/4885PRMT5 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback